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Abstract: Aerosol delivery of Iloprost is a promising therapeutic approach. The aim of this 
study was to determine the output of an ultrasonic nebulizer in different ventilation set-ups at 
the tip of different endotracheal tubes.
Method: In set-up A, an ultrasonic nebulizer was connected directly to the endotracheal tube. 
In set-up B, the nebulizer was incorporated into the inspiratory limb of the ventilator circuit; a 
bypass arrangement allowed to selectively direct the exspiratory air discharged from the model 
lung. The test lungs were ventilated through a standard endotracheal tube (ET) and through a 
double-lumen tube (DLT). The nebulizer was ﬁ  lled with 5 ml of a Tc-99m 0.9%-NaCl solution. 
After nebulization, distribution of radioactivity was detected by gamma scintigraphy.
Results: Set-up A, ventilation in volume-controlled mode (VCV) via an ET: Delivered dose 
(1.61 ± 0.41 ml), nebulization time 10.13 ± 1.71 min. Set-up A, pressure-controlled ventilation 
(PCV), via a DLT: Delivered dose (1.33 ± 0.88 ml), nebulization time 13.27 ± 2.58 min. Set-up B, 
VCV mode via an ET: Delivered dose (1.57 ± 0.44 ml), nebulization time (25.9 ± 3.8 min). Set-up 
B, PCV mode, via a DLT: Delivered dose (1.3 ± 0.17 ml), nebulization time (25.6 ± 4.0 min). 
Set-up B did not yield a signiﬁ  cantly higher output (p  0.05), but the nebulization time was 
signiﬁ  cantly longer (p  0.05) compared with set-up A.
Conclusion: Set-ups which involve connecting the nebulizer directly to an ET or a DLT exhibit 
sufﬁ  cient output of aerosol and short nebulization times.
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Introduction
Delivery of drugs in aerosolized form to the airways of patients with pulmonary dis-
eases is a common clinical practice, and the use of nebulized drugs during mechanical 
ventilation is increasing. Numerous drugs have been investigated for possible delivery 
via aerosol. In most instances, the drug has a topical or direct effect on airway or lung 
tissue while keeping systemic exposure to a minimum (Shapiro and Peruzzi 2000; 
Anderson 2005). Inhaled Iloprost, a stable long-acting prostacycline analogue, provides 
an effective therapy for patients with severe pulmonary hypertension (Olschewski and 
Simonneau 2002). It has been shown that the employment of ultrasonic nebulizers 
offers more effective alveolar deposition of Iloprost in severe pulmonary hypertension 
(PHT), as compared with conventional jet nebulization devices (Gessler and Schmehl 
2001). More recent studies have suggested that intraoperative inhalation of Iloprost is 
a therapy option in case of imminent right heart failure in patients with PHT (Langer 
and Wilhelm 2003). Acute right heart failure is a life-threatening situation, and the 
drugs need to be administered quickly and efﬁ  ciently.
Using mechanical ventilation in combination with aerosol administration of drugs is 
an established practice in intensive care units; the set-up is arranged such that only the Drug Design, Development and Therapy 2008:2 2
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inspiratory air ﬂ  ow passes through the nebulizer (Miller and 
Amin 2003). The underlying assumption is that a signiﬁ  cant 
amount of the drug contained in the volume of air common 
to the inspiratory and expiratory pathways will be lost on 
expiration. Modern anesthetic machines do not include a 
nebulization function. This disadvantage becomes particu-
larly evident in intra-operative settings when connecting the 
nebulizer to the circle system of an anesthetic machine might 
prove laborious (Wilhelm and Grundmann 2004). The task is 
therefore to establish a convenient in vitro model that helps 
evaluate the amount of aerosol delivered through an ET tube 
under conditions similar to an intra-operative situation. We 
thus explored the inﬂ  uence that a quick attachment of an 
ultrasonic nebulizer to an endotracheal tube has on efﬁ  cient 
drug output and nebulization time. The majority of patients 
who undergo lung operation are not ventilated through a 
standard tube, but through a double-lumen tube (DLT) that 
allows side-separated ventilation to a modiﬁ  ed ventilation 
pattern. In addition, successful therapy with agents such as 
surfactant and prostaglandins requires targeting the aerosols 
to speciﬁ  c sites within the lung (Dhand 2003). Another 
interesting aspect was to ﬁ  nd out whether or not different 
ventilator modes and types of endotracheal tubes inﬂ  uence 
aerosol delivery performance.
Materials and methods
To assess the aerosol output of a nebulizer in different arti-
ﬁ  cial ventilation set-ups, an ultrasonic nebulizer (Multisonic 
Schill GmbH, Probstzella, Germany) was connected to a 
Centiva/5 Ventilator (Datex Ohmeda, Duisburg, Germany). 
Methods to integrate the nebulizer into the ventilation circuit 
fell into two different approaches.
The ﬁ  rst method encompassed a mainstream set-up (A), 
in which the nebulizer is placed between the endotracheal 
tube and the ventilator circuit. Consequently, inhalation 
and exhalation gases ﬂ  ow into and out of the nebulizer that 
is connected directly to the tube. At the end of the tube, an 
inhalation heat and moisture exchanger (Pall ﬁ  lter BB50TE), 
as well as a resistance of 5 kPa/l/s (10 kPa/l/s with the double-
lumen tube) were placed between the tube and a test lung 
(2.3 l with Y-piece). The nebulizer air inlet was connected 
to the Centiva/5 tubing via an exhalation heat and moisture 
exchanger (Pall ﬁ  lter BB50TE, Pall GmbH, Dreieich, Ger-
many) (See Figure 1).
The second set-up comprised a bypass set-up (B), in 
which the nebulizer was placed between endotracheal tube 
and respirator. This arrangement allowed only the inspiratory 
air ﬂ  ow to pass through the nebulizer.
This set-up involved connecting the upper part of the 
nebulizer to the endotracheal tube via a tube and a T-piece. 
Centiva/5 tubing and an exhalation heat and moisture 
exchanger (Pall Filter BB50TE, Pall GmbH, Dreieich, 
Germany) were attached to the other side of the T-piece. 
Another T-piece was inserted into the inhalation path of the 
Centiva/5 tubing. As a result it became possible to connect 
an additional 20 mm tube to the air inlet of the nebulizer. 
The nebulizer inhalation valve remained in its original posi-
tion. At the end of the endotracheal tube, an inhalation heat 
and moisture exchanger (Pall ﬁ  lter BB50TE, Pall GmbH, 
Dreieich, Germany), as well as a resistance of 10 kPa/l/s, 
Figure 1 Set up A.
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was placed between the endotracheal tube and a test lung 
(2.3 l) (See Figure 2).
Aerosol nebulizer output was measured in two different 
ventilation set-ups at the tip of two different endotracheal 
tubes.
The test lung was managed by volume control ventilation 
(FiO2 21%, tidal volume 700 ml, ventilation rate 12/min, 
I:E 1:2; peak pressure max. 30 cm H2O, PEEP 3 cm H20, 
ﬂ  ow 30 l/min) via a standard endotracheal tube (7.5 ID 
single lumen, Portex, Kirchseeon/Eglharting, Smiths Medi-
cal Germany).
Pressure-controlled ventilation was maintained in all 
tests involving the use of a double-lumen tube (Broncho 
Cath 37FR, Tyco Healthcare Deutschland GmbH, Neus-
tadt, Germany) (FiO2 21%, ventilation rate 12/min, I:E 1:2; 
Bi-level ramp 0.2 seconds; Peak pressure inspiratory 30 cm 
H2O, PEEP 3 cm H20, trigger sensitivity 20 l/min).
In all experiments, the nebulizer was ﬁ  lled with 5 ml of 
radio labelled 0.9%-NaCl solution and placed into the set-
up as described above. Said Tc-99m 0.9%-NaCl solution 
(Tyco Healthcare, Germany) had a speciﬁ  c activity of app. 
1.25 MBq (Mega Bequerel) per ml. 6 samples of 1 ml each 
of this solution were placed into a scintillation counter that 
determined the speciﬁ  c activity of the solution. The nebulizer 
switched off automatically as soon as the medicament was 
used up, and/or as soon as the nebulizer´s residual volume 
of 0.6 ml was reached. The Centiva/5 was switched on. 
After the Centiva/5 had reached steady state, the nebulizer 
was switched on. Nebulization was performed until the 
nebulizer switched off automatically. The nebulization time 
was recorded.
The set-up was dismounted, and the deposits were ana-
lyzed using a gamma scintillation counter (Perkin Elmer, 
Germany). The deposits stemmed from the inhalation 
heat and moisture exchanger, endotracheal tube, residue 
in nebulizer, upper part of nebulizer, exhalation heat, and 
moisture exchanger. In set-up B, the material deposit that 
had accumulated inside the tube leading to the nebulizer was 
analyzed. Ambient conditions (humidity, temperature) were 
recorded before each measurement.
Data evaluation
In order to determine the amount of aerosol present on each 
heat and moisture exchanger, the activity measured in the 
sample heat and moisture exchangers was divided by the 
speciﬁ  c activity values. Similar calculations were performed 
for the other parts of the set up.
Statistical analysis
The data are presented as mean ± standard deviation; a two-
group comparison was done with two – sample t-test and 
Mann-Whitney U-test. p-values 0.05 were considered 
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statistically significant. All statistical analyses were 
carried out using SPSS version 14.0 for Windows (SPSS 
Inc, Chicago, Illinois, USA).
Results
Each measurement was performed three times. The mass 
balance record was determined from all measurements. 
Recovery rates ranged from 95.9% to 99.6%. All measure-
ments were made at ambient temperatures ranging from 22 °C 
to 24 °C and relative humidities between 56% and 61%.
In the test lung that received volume-controlled venti-
lation (VCV) via a standard endotracheal tube (set-up A, 
mainstream set-up), the mean dose delivered amounted to 
1.61 ± 0.41 ml. Mean aerosol loss resulting from impaction 
on the tubings: 1.53 ± 0.02 ml, mean residual volume left 
in the nebulizer: 1.7 ± 0.07 ml, mean nebulization time: 
10.13 ± 1.71 min (See Table 1).
In the lung model that received pressure-controlled venti-
lation (PCV) via a double-lumen tube (set-up A, mainstream 
set up), the mean delivered dose amounted to 1.33 ± 0.88 ml. 
Mean aerosol loss resulting from impaction on the tubings: 
1.62 ± 0.17 ml, mean residual volume left in the nebulizer: 
1.89 ± 0.14 ml, mean nebulization time: 13.27 ± 2.58 min 
(See Table 2).
The set-up B (bypass set-up) lung model that was man-
aged by volume-controlled ventilation (VCV) via a standard 
endotracheal tube showed the following results: mean dose 
delivered was 1.57 ± 0.44 ml, mean residual volume left 
in the nebulizer: 1.87 ± 0.1 ml, mean nebulization time: 
25.9 ± 3.8 min (see Table 3).
The set-up B (bypass set up) test lung that received 
pressure-controlled ventilation (PCV) via a double-lumen 
tube exhibited the following results: mean dose delivered: 
1.30 ± 0.17 ml, mean aerosol loss resulting from impaction 
in tubing: 1.38 ± 0.21 ml, mean residual volume left in the 
nebulizer: 2.2 ± 0.15 ml, mean nebulization time: 25.6 min ± 
4.07 min (See Table 4).
After nebulization, no signiﬁ  cant differences were seen 
in the amounts of aerosol trapped in the set-up A inhalation 
heat and moisture exchanger (mainstream set up) and that 
of set-up B (bypass set-up) (1.5 ± 0.2 ml vs. 1.4 ± 0.3 ml) 
(p = 0.82); (p = 0.63; u-test) (Figure 3).
Set-up A (mainstream set up), however, offered a sig-
niﬁ  cantly reduced nebulization time compared to set-up B 
(11.7 ± 2.6 min vs. 25.8 ± 3.5 min) (p = 0.0001); (p = 0.004; 
u-test).
Set-up A had a signiﬁ  cantly larger amount of aerosol in 
the exhalation heat and moisture exchanger than set-up B 
(1.47 ± 0.08 ml vs. 0.26 ± 0.23 ml) (p = 0.0001); (p = 0.004; 
u-test).
A large residual amount (0.89 ± 0.16 ml) remained in the 
bypass tube of set-up B.
Discussion
This was the ﬁ  rst ever study aimed at measuring both the 
output and the nebulization time from an ultrasonic nebulizer 
which was connected directly to a standard endotracheal 
tube and to a double-lumen tube with no change in ventilator 
settings. These data were compared with data achieved 
in a bypass set-up involving a nebulizer placed between 
endotracheal tube and respirator in such a way that it was 
incorporated only into the inspiratory limb of the ventilator 
circuit; a bypass line was in place for selectively directing 
the exspiratory air discharged from the test lungs.
Surprisingly enough, the bypass set-up (B) was not clearly 
superior to the mainstream set-up (A) with respect to the total 
output at the tip of the endotracheal tube. The reasons for this 
are that the advantage provided by the bypass circuit, namely 
that the nebulizer releases aerosol only during inhalation, 
was almost eliminated because a large amount of aerosol 
accumulated inside the additional tubing. The nebulization 
time for the bypass set-up (B) was more than twofold greater 
than that of the mainstream set-up (A). In the intra-operative 
situation particularly, attaching the nebulizer device directly 
Table 1 Set up A.  Volume-controlled ventilation (VCV)
  Run 1   Run 2   Run 3  Mean 
 [ml]  [ml]  [ml]  [± SD]
Inhalation ﬁ  lter  1.58  1.66  1.60  1.61 ± 0.41
Endotracheal tube  0.11  0.12  0.07  0.10 ± 0.26
Exhalation ﬁ  lter  1.43  1.42  1.44  1.43 ± 0.01
Residue in nebulizer  1.67  1.65  1.79  1.70 ± 0.07
(including all nebulizer parts)
Nebulization time [min]  9.0  12.1  9.3  10.13 ± 1.71
Table 2 Set-up A. Pressure-controlled ventilation (PCV)
  Run 1   Run 2   Run 3   Mean 
 [ml]  [ml]  [ml]  [± SD]
Inhalation ﬁ  lter  1.43  1.26  1.30  1.33 ± 0.88
Endotracheal tube  0.16  0.20  0.12  0.16 ± 0.04
Exhalation ﬁ  lter  1.61  1.42  1.54  1.52 ± 0.09
Residue in nebulizer  1.73  2.00  1.95  1.89 ± 0.14
(including all nebulizer parts) 
Nebulization time [min]  14.5  15.0  10.3  1.27 ± 2.58Drug Design, Development and Therapy 2008:2 5
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to the endotracheal tube should be the preferred method. 
The shortcoming of this method, namely that a somewhat 
lower amount of aerosol is provided, is outweighed by the 
advantage of faster treatment. Moreover, shorter nebulization 
times result in reduced inﬂ  uences from other factors affecting 
aerosol performance during nebulization, such as changes in 
temperature, concentration, surface tension, viscosity, and 
saturated vapor pressure of the nebulizing solution (Steckel 
and Eskandar 2003). According to expectations, the use of a 
double-lumen tube was associated with a somewhat higher 
loss of aerosol in the tube as compared with a standard 
endotracheal tube; this can be explained by the fact that it 
provides a greater surface area of contact.
The mainstream set-up (A) comprising an ultrasonic 
nebulizer also has advantages over nebulizers which require an 
additional source of gas. Alterations in VT are avoided, and ﬂ  ow-
measurement components that can be found in some ventilator 
circuit systems are not allowed to get damaged (Hess 1994).
The method chosen for our study, ie, to connect the nebu-
lizer directly to an ET or DLT without using supplemental gas 
to drive the nebuliser, yielded a signiﬁ  cantly higher aerosol 
output (Set up A 32%, Set up B 36%) compared with results 
of studies conducted by O´Doherty and Thomas (1992, 1993) 
using several ultrasonic and jet nebulizer devices.
These studies reported maximum output levels of 10%. 
Only one nebulizer could provide an 8% increase through a ﬁ  ll-
ing volume that totalled six times that of the others (O’Doherty 
and Thomas 1992; Thomas and O’Doherty 1993).
The Servo 945 nebulizer driver had a profound inﬂ  uence 
on the output of some of the aerosol delivery devices.
A variety of new devices that deliver drugs to the lung 
with high efﬁ  ciency can be employed for drug delivery during 
mechanical ventilation (Dhand 2004). But most of the data 
relating to drug dosage have been obtained from spontane-
ously breathing patients (Geller 2005). Data from such in 
vitro assays are very useful in guiding aerosol therapy during 
mechanical ventilation. Several studies have recently been 
conducted to determine the suitability of various nebulizer 
devices (Di Paolo and Pannatier 2005; Vecellio and Guerin 
2005). Ultrasonic-nebulizer aided delivery of aerosolized 
Iloprost into the lungs of ventilated patients with pulmonary 
hypertension is becoming increasingly important. Iloprost 
aerosol administration offers the advantage of avoiding the 
effects of an intravenous therapy on systemic circulation. 
As for the nebulization of Iloprost, ultrasonic nebulizers 
provide far superior efﬁ  ciency compared to customary com-
pressed-air nebulizer devices (Gessler and Schmehl 2001). 
A particularly noteworthy feature is that the aerosol particles 
generated are so small that they can migrate into the deeper 
regions of the lung (Kohler and Sollich 2003).
The ultrasonic nebulizer device used in the present study 
generates particles in the size range of 3.2 μg to 3.5 μg.
Limitations
Although only one ultrasonic nebulizer was investigated in 
this study, the ﬁ  ndings allow the conclusion that the loss in 
all the various ultrasonic nebulizers will be of the same order 
of magnitude as the loss encountered in the present bypass 
arrangement.
The data generated from the experiments described above 
refer only to the nebulized amount determined directly at the 
tip of the endo-tracheal tube.
In this study, we have not evaluated in vivo the actual 
amount of aerosol deposition within the alveoli after nebu-
lization.
Information about how much aerosol is able to go deeper 
into the lungs cannot reliably be derived from these data.
The in vitro experiments described above were done 
primarily to assess the suitability of different ultrasonic 
nebulizer arrangements without exposing patients to unnec-
essary radiation. Respiratory tract deposition data of aerosol 
particles after nebulization are well known from other authors 
Table 3 Set-up B.   Volume-controlled ventilation (VCV)
  Run 1   Run 2  Run 3   Mean 
 [ml]  [ml]  [ml]  [± SD]
Inhalation ﬁ  lter  1.91  1.73  1.07*  1.57 ± 0.44
Endotracheal tube  0.23  0.26  0.17  0.22 ± 0.05
Exhalation ﬁ  lter  0.21  0.19  0.72  0.37 ± 0.3
Tube nebulizer  0.72  0.8  0.99  0.84 ± 0.14
Endotracheal tube
Residue in nebulizer   1.77  1.98  1.87  1.87 ± 0.1
(including all nebulizer parts)
Nebulization time [min]  23.9  30.3  23.6  25.9 ± 3.8
Table 4 Set-up B. Pressure-controlled ventilation (PCV)
  Run 1   Run 2  Run 3  Mean 
  [ml] [ml] [ml] [± SD]
Inhalation ﬁ   lter  1.22 1.50 1.18*  1.30  ± 0.17
Endotracheal  tube  0.30 0.24 0.26 0.27  ± 0.30
Exhalation ﬁ   lter  0.11 0.139  0.21 0.15  ± 0.05
Tube  nebulizer  0.81 0.92 1.15 0.96  ± 0.17
Endotracheal tube 
Residue  in  nebulizer  2.4 2.1 2.2 2.2  ± 0.15
(including all nebulizer parts)
Nebulization  time  [min]  30.1 22.2 24.4 25.6  ± 4.07Drug Design, Development and Therapy 2008:2 6
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(Stahlhofen and Gebhart 1980; Morrow 1986; Kohler and 
Sollich 2003).
Conclusion
A set-up in which the nebulizer is connected directly to 
an ET or DLT achieved higher aerosol output and shorter 
nebulization times than a bypass set-up. The ideal nebuliza-
tion conditions remain to be established. However, we have 
shown that the method involving the use of an ultrasonic 
nebulizer to intra-operatively administer a nebulized drug 
directly to a standard endotracheal tube or a double-lumen 
tube yields convincing results.
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